Immunotherapy | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Aung Naing
B01=Joud Hajjar
Category1=Non-Fiction
Category=MJCL
Category=MJCM
COP=Switzerland
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€100 and above
PS=Active
softlaunch

Immunotherapy

English

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches.  Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions.

The  books chapters are written by a diverse cast of experts conducting cutting-edge research,providing the reader with the most up-to-date science.

See more
Current price €198.08
Original price €212.99
Save 7%
Age Group_Uncategorizedautomatic-updateB01=Aung NaingB01=Joud HajjarCategory1=Non-FictionCategory=MJCLCategory=MJCMCOP=SwitzerlandDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 178 x 254mm
  • Publication Date: 17 Apr 2020
  • Publisher: Springer Nature Switzerland AG
  • Publication City/Country: Switzerland
  • Language: English
  • ISBN13: 9783030410070

About

Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology Dr. Naings research interests are (1) identifying immunologic biomarkers of response to immunotherapy (2) predicting primary and secondary resistance to immunotherapy (3) developing immunotherapeutic strategies to overcome resistance and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Childrens Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology and the Early Career Immunologist Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in primary immunodeficiency disorders and cancer immunotherapy.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept